Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1

The challenge in HER2-overexpressing breast cancer therapy lies in creating an effective target therapy to overcome treatment resistance. Monoclonal antibodies and target gene silencing by siRNA are two potential strategies that have been widely developed for treating HER2-positive breast cancer. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pengnam, Supusson, Opanasopit, Praneet, Rojanarata, Theerasak, Yingyongnarongkul, Boon-ek, Thongbamrer, Chopaka, Plianwong, Samarwadee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610066/
https://www.ncbi.nlm.nih.gov/pubmed/37896184
http://dx.doi.org/10.3390/pharmaceutics15102424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610066/
https://www.ncbi.nlm.nih.gov/pubmed/37896184
http://dx.doi.org/10.3390/pharmaceutics15102424

Ejemplares similares